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Abstract
Visual evoked potential (VEP) plasticity is a promising assay for noninvasive examination of long-term potentiation
(LTP)-like synaptic processes in the cerebral cortex. We conducted longitudinal and cross-sectional investigations of
VEP plasticity in controls and individuals with bipolar disorder (BD) type II. VEP plasticity was assessed at baseline, as
described previously (Elvsåshagen et al. Biol Psychiatry 2012), and 2.2 years later, at follow-up. The longitudinal sample
with VEP data from both time points comprised 29 controls and 16 patients. VEP data were available from 13
additional patients at follow-up (total n= 58). VEPs were evoked by checkerboard reversals in two premodulation
blocks before and six blocks after a plasticity-inducing block of prolonged (10 min) visual stimulation. VEP plasticity was
computed by subtracting premodulation VEP amplitudes from postmodulation amplitudes. Saliva samples for cortisol
analysis were collected immediately after awakening in the morning, 30 min later, and at 12:30 PM, at follow-up. We
found reduced VEP plasticity in BD type II, that impaired plasticity was present in the euthymic phases of the illness,
and that VEP plasticity correlated negatively with depression severity. There was a positive association between VEP
plasticity and saliva cortisol in controls, possibly reflecting an inverted U-shaped relationship between cortisol and
synaptic plasticity. VEP plasticity exhibited moderate temporal stability over a period of 2.2 years. The present study
provides additional evidence for impaired LTP-like cortical plasticity in BD type II. VEP plasticity is an accessible method,
which may help elucidate the pathophysiological and clinical significance of synaptic dysfunction in psychiatric
disorders.
Introduction
Bipolar disorder (BD) type I and II affect 2–3 % of the
population and can lead to marked impairments in social
and occupational functioning1–3. The estimated herit-
ability of BD is ~ 0.74,5, yet its precise pathophysiological
basis remains unknown. Consequently, current
therapeutic options may not target fundamental illness
processes and remain insufficient for a substantial num-
ber of patients6,7. The clarification of central pathophy-
siological mechanisms is therefore a critical step toward
improved outcomes in BD.
Synaptic dysfunction is one of the leading candidate
mechanisms across psychiatric illnesses8–13. In particular,
preclinical studies and genetic investigations have impli-
cated synaptic plasticity in the etiology and treatment of
BD, major depressive disorder (MDD), autism spectrum
disorder, and schizophrenia13–23. Despite these findings,
there is a paucity of clinical evidence supporting synaptic
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dysfunction in psychiatric disorders, mainly due to a lack
of methods for noninvasive measurements of synaptic
function and plasticity in humans. However, electro-
encephalography (EEG)-based measurement of visual
cortex plasticity has in recent years emerged as a pro-
mising assay for in vivo assessment of synaptic function
and plasticity24,25. Previous studies showed that repeated
visual stimulation-induced increases of the human visual
evoked potential (VEP), i.e., an EEG signal that primarily
reflects postsynaptic potentials in the visual cortex26–30.
Further investigations found that VEP plasticity was
reduced in BD type II, MDD, and schizophrenia28–30.
Although the precise neural substrates for VEP plasticity
in humans remain to be clarified, detailed studies in
rodents showed that VEP increases induced by repetitive
visual stimulation is long-lasting, stimulus-specific, and
depends on synaptic N-methyl-D-aspartate (NMDA) and
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptors and protein kinase Mζ31–33. These are all
core features of long-term potentiation (LTP), which is
the best characterized form of synaptic plasticity34–36.
Together, these results indicate that VEP plasticity is
reduced and may reflect impairments of cortical LTP-like
synaptic processes, in BD type II, MDD, and
schizophrenia.
Despite these promising findings, more research is
needed to clarify the mechanisms, translational potential,
and clinical utility of VEP plasticity in BD and other
psychiatric illnesses. Impaired VEP plasticity across psy-
chiatric illnesses28–30 may suggest that nonspecific
mechanisms such as stress- and cortisol-related synaptic
dysfunction37,38 could underlie the plasticity reductions.
Moreover, the relationships between VEP plasticity and
clinical characteristics of psychiatric illnesses remain to be
clarified. In addition, there are to our knowledge no
longitudinal studies of VEP plasticity and its temporal
stability in healthy volunteers and patient groups remains
unknown.
We previously found plasticity of the VEP in healthy
controls and reduced plasticity in BD type II29.
Here, we conducted longitudinal and cross-sectional
investigations of VEP plasticity in individuals with BD
type II and controls with the following main aims: (1) to
test the reproducibility of impaired VEP plasticity in BD
type II and to assess the relationship between mood state
and plasticity, (2) to examine the relationship between
saliva cortisol and VEP plasticity in controls and BD type
II, and (3) to examine the temporal stability of VEP
plasticity.
Methods and materials
Participants and clinical examinations
We assessed VEP plasticity at Oslo University Hospital
in 40 controls and 26 individuals with BD type II at
baseline, as described previously29. At follow-up, on
average 2.2 years later, 33 of the controls and 18 of the
patients again underwent the VEP plasticity examinations.
Two patients and four controls were excluded from the
analyses owing to technical issues during EEG recording
and insufficient data quality, thus the longitudinal sample
comprised 29 controls and 16 patients. Moreover,
16 additional patients and one new control were included
at follow-up to further assess the relationship between
VEP plasticity and saliva cortisol and mood state.
Owing to technical issues and insufficient data quality,
three of the new patients and the new control were
excluded from the analyses. Thus, the cross-sectional
patient sample at follow-up included 29 participants. In
controls, the longitudinal sample and the cross-sectional
sample at follow-up were identical and comprised 29
individuals.
The patients were recruited from psychiatric
outpatient clinics in the Oslo area. Clinical examinations
at baseline and follow-up were carried out by senior
psychiatrists (i.e., authors EB, BB, and UFM) at a
university department specializing in the evaluation
and treatment of mood disorders. Axis I diagnoses
and psychiatric comorbidities were determined with the
Mini-International Neuropsychiatric Interview, DSM-IV
criteria version 5.039. Alcohol and drug use were assessed
with the Alcohol Use Scale and the Drug Use Scale40,
respectively. Mood state was assessed at the day of EEG
recording for the large majority of participants and within
3 days of the recording for all participants. Assessments
were carried out by trained physicians (i.e., authors EB,
BB, UFM, and TE) using the Montgomery–Asberg
Depression Rating Scale (MADRS)41 and the Young
Mania Rating Scale (YMRS)42. These physicians under-
went a day course of MADRS and YMRS prior to
the present study, which included estimation of their
intraclass correlation coefficient3.1 (ICC3.1); all ICC3.1’s
were > 0.8.
Controls with no previous or current psychiatric illness
were recruited through local advertising and underwent a
full examination similar to that of the patients at baseline
and follow-up. The exclusion criteria for all subjects were:
age below 18 or above 50 years, history of neurological or
other severe chronic somatic disorder, and pregnancy.
One patient had experienced a mild head injury with loss
of consciousness for > 1min. However, the patient did not
have any clinical or magnetic resonance imaging-
detectable cerebral sequela and was included in the
study. Otherwise, no participant reported head injury with
loss of consciousness for > 1min. All subjects had normal
or corrected-to-normal visual acuity. The Regional Ethical
Committee of South-Eastern Norway approved the study,
and all subjects provided written informed consent to
participate.
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Experimental paradigm
The experimental paradigm described by Normann
et al.28. was used at baseline29 and follow-up. VEPs were
evoked by checkerboard reversals (check size= 0.5°; 2
reversals/sec) in two premodulation blocks before and six
blocks after a plasticity-inducing modulation block (Fig.
1). In each pre- and postmodulation block, 40 checker-
board reversals were presented within 20 s. In the mod-
ulation block, VEPs were evoked by checkerboard
reversals (check size= 0.5°; 2 reversals/sec) for 10min.
The premodulation blocks were initiated 2 and 8 min after
the start of the experiment, and the modulation block was
initiated 2 min after the last premodulation block. Then,
the postmodulation blocks were performed 2, 8, 12, 18,
22, and 28 min after the end of the modulation block. A
gray screen was displayed between checkerboard stimu-
lation. Participants focused on a filled red circle (0.1°) in
the center of the screen during the experiment. They were
monitored throughout the experiment to ensure that they
followed instructions and maintained attention, and were
allowed to listen to music. The visual stimuli were pre-
sented with E-Prime 1.1 (Psychology Software Tools,
Sharpsburg, Pennsylvania) on a Samsung Syncmaster
2493HM LCD screen (Samsung Electronics Nordic AB,
Oslo, Norway). To ensure high timing accuracy, a pho-
todiode from the Black Box Toolkit® (Sheffield, UK) was
used and VEP latencies were corrected accordingly.
Recording and analysis of the VEP
VEP plasticity was assessed using EEG data from the Oz
electrode at both time points. The baseline examination
also included mismatch negativity and oddball paradigms.
Continuous EEG activity was therefore recorded from 15
monopolar silver/silver chloride electrodes for analyses of
these paradigms at baseline. However, the follow-up
examination only comprised the VEP plasticity paradigm
and only three electrodes were therefore used (O1, Oz,
and O2). All impedances were maintained below 5 kΩ
and the ground and reference electrodes were attached to
the forehead (AFz). Eye movements were recorded with
bipolar electrodes placed at the sub- and supraorbital
regions and at the lateral canthi of each eye. EEG activity
was recorded at 250 Hz with an amplifier band-pass of
0.05–100 Hz. Offline EEG analysis was conducted with
EEGLAB43, run on MATLAB 7.6.0. (MathWorks, Natick,
Massachusetts). The EEG was first high-pass filtered at
1 Hz, and segmented into epochs starting 150msec before
and continuing 350msec after the onset of each check-
erboard reversal. All epochs containing eye movement-
related activity were removed from analyses.
Epochs were then shortened (−50 to 350msec) and
baseline-corrected (−50 to 0msec), and epochs with
amplitudes exceeding ± 100 µV on any of the occipital
channels (O1, Oz, O2) were rejected. The epoched EEG
was finally low-pass filtered at 30 Hz and averaged to
block-specific VEPs. Peak amplitudes and latencies for the
C1, P1, N1, and the P1–N1 peak-to-peak amplitudes were
obtained from the Oz electrode at the occipital head;
amplitudes were measured relative to the 50msec
baseline.
Saliva collection and cortisol analysis
Saliva samples for cortisol analysis were collected using
Salivette® Cortisol swabs (Sarstedt AG & Co, Nümbrecht,
Germany) and analyzed with a Cortisol Saliva Lumines-
cence Immunoassay (IBL International, Hamburg, Ger-
many) according to the manufacturers´ instructions.
Saliva samples were obtained the day after the VEP
Fig. 1 Experimental setup. The experimental paradigm described by Normann et al.28 was used at baseline, as described previously, and at follow-
up. VEPs were evoked by checkerboard reversals (check size= 0.5°; 2 reversals/sec) in two premodulation blocks before and six blocks after a
plasticity-inducing modulation block consisting of 10 min of checkerboard reversal stimulation (check size= 0.5°; 2 reversals/sec). The premodulation
blocks were initiated 2 and 8min after the start of the experiment, and the modulation block was initiated 2 min after the last premodulation block.
The postmodulation blocks were performed 2, 8, 12, 18, 22, and 28min after the end of the modulation block. A gray screen was displayed in the
intervals between checkerboard stimulation. Participants were instructed to focus on a filled red circle (0.1°) in the center of the screen during the
experiment and were allowed to listen to music. The participants were monitored throughout the experiment to ensure that they followed
instructions and maintained attention. VEP, visual evoked potential
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experiment at three times: immediately after awakening in
the morning, 30 min after the first collection, and at
12:30 PM. Participants were instructed to not brush teeth
and to refrain from physical activity, nicotine, and caffeine
before saliva collection and to not eat or drink the last
30 min before the samples were obtained. Saliva cortisol
was averaged across the three collections. We also com-
puted the cortisol awakening response (saliva cortisol
30 min post awakening minus cortisol at awakening), as a
previous study found that the cortisol awakening response
was associated with transcranial magnetic stimulation
(TMS)-induced motor cortex plasticity44. Complete cor-
tisol data were missing for one control and two indivi-
duals with BD type II.
Statistical analyses
All statistical analyses were conducted with SPSS ver-
sion 24 for Windows (IBM Corp., Armonk, NY) and a
two-tailed p value of < .05 was considered significant. VEP
amplitudes from the two premodulation and from the six
postmodulation recordings were averaged as premodula-
tion and postmodulation VEP, respectively. To examine
the effect of the modulation block on the VEP, the C1, P1,
N1, and P1–N1 premodulation amplitudes were com-
pared with the corresponding postmodulation amplitudes
with repeated measures analysis of variance (ANOVA) in
controls and patients separately. VEP plasticity was
computed by subtracting premodulation VEP amplitudes
from the corresponding postmodulation amplitudes.
Table 1 Demographic and clinical characteristics of the longitudinal and the cross-sectional samples of patients with
bipolar disorder type II and healthy controls
Longitudinal samplea Cross-sectional sample at follow-up









Age, years, mean (SD) 32.7 ± 7.5 33.1 ± 9.4 0.87 35.5 ± 7.9 35.6 ± 9.6 0.99
Female, n (%) 9 (56) 16 (55) 0.94 19 (66) 16 (55) 0.42
Education level, n (%)
0–10 years 2 (12.5) 0 (0) 2 (7) 0 (0)
11–13 years 4 (25) 3 (10) 8 (28) 2 (7)
14–17 years 8 (50) 11 (38) 9 (31) 11 (38)
17+ years 2 (12.5) 15 (52) 0.02 10 (34) 16 (55) 0.07
MADRS, mean (SD) 11.9 ± 6.5 1.3 ± 2.2 < 0.001 8.8 ± 6.8 1.3 ± 1.6 < 0.001
YMRS, mean (SD) 3.0 ± 3.4 0.3 ± .8 < 0.001 2.4 ± 2.5 0.3 ± .7 < 0.001
Euthymia (MADRS < 11, YMRS < 8) 10 18
Depression (MADRS > 11) 5 8
Hypomania (YMRS ≥ 8) 1 3
Medication, n (%)
Unmedicated 6 (38) 7 (24)
Antidepressants 6b (38) 7c (24)
Lamotrigine 6 (38) 16 (55)
Lithium 1 (6) 0 (0)
Quetiapine 1 (6) 3 (10)
Methylphenidate 0 (0) n.a. 2 (7) n.a.
Duration of illness, years, mean (SD) 17.3 ± 8.1 n.a. 18.0 ± 7.3 n.a.
Social phobia, n (%) 4 (25) 0 (0) 10 (34) 0 (0)
Panic disorder, n (%) 6 (38) 0 (0) 18 (62) 0 (0)
General anxiety disorder, n (%) 2 (13) 0 (0) 2 (7) 0 (0)
aCharacteristics at baseline
bAntidepressants were escitalopram, citalopram, bupropion, mirtazapine, and fluoxetine
cAntidepressants were escitalopram, citalopram, bupropion, mirtazapine, venlafaxine, sertraline, and mianserin
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Saliva cortisol was compared between groups using
ANOVA. VEP plasticity scores were subjected to ANO-
VAs and analyses of covariance, after testing the
assumption of homogeneity of regression slopes, to
examine the effects of group, covarying for saliva cortisol,
premodulation VEP amplitudes, and educational level (in
the case of significant group differences for the latter
variables) and the effect of medication (controls vs.
unmedicated patients vs. medicated patients, Bonferroni
corrected for the three contrasts). The relationships
between VEP plasticity and mood state, saliva cortisol,
and other clinical variables were assessed with Pearson
correlation, Spearman´s rank correlation, and repeated
measures ANOVA. The temporal stability of VEP plasti-
city was examined using Pearson correlation and ICC3.1.
Fig. 2 VEP plasticity of the longitudinal sample at follow-up. a Grand average premodulation (blue) and postmodulation (red) VEP in controls (n
= 29). The modulation block resulted in significant plasticity of the P1, N1, and P1–N1 amplitudes. b Grand average premodulation (blue) and
postmodulation (red) VEP in patients with BD type II (n= 16). There was no significant P1, N1, or P1–N1 plasticity in the patient group. c P1–N1
plasticity was significantly reduced in patients with BD type II relative to controls. There was no significant group difference in C1 or N1 plasticity;
however, there was a trend toward reduced P1 plasticity in patients (p= 0.07). The group difference in P1–N1 plasticity remained significant after
controlling for cortisol, premodulation amplitude, and educational level. ***p < 0.001. Error bars represent the s.e.m. d Temporal stability of VEP
plasticity in controls and patients with BD type II. There was a significant positive correlation between baseline and follow-up P1 plasticity and e N1
plasticity, but not f P1–N1 plasticity in controls. g There was no significant correlation between baseline and follow-up P1 plasticity or h N1 plasticity,
however, i there was a significant correlation for baseline and follow-up P1–N1 plasticity in patients with BD type II.VEP, visual evoked potential. BD,
bipolar disorder
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Results
Demographic and clinical variables
Demographic and clinical variables for the longitudinal
and the cross-sectional samples are shown in Table 1.
There were no significant group differences in age or
gender. In the longitudinal sample, controls had a higher
educational level than patients; otherwise there were no
significant group differences. Eighteen out of 29 patients
were euthymic (MADRS score < 11 and YMRS score < 8),
eight patients were depressed (MADRS score 12–23) and
three patients were hypomanic (YMRS score 8) at follow-
up examinations.
VEP plasticity of the longitudinal sample
VEP plasticity of the longitudinal sample at baseline
We previously reported significant VEP plasticity in
healthy controls and impaired plasticity of the P1–N1
amplitude in individuals with BD type II at baseline (when
the whole sample of 40 controls and 26 individuals with
BD type II was analyzed)29. Here, we reran the VEP
analyses for the longitudinal sample at baseline (n= 45)
and found no significant group differences in the C1, P1,
N1, or the P1–N1 amplitudes of the premodulation blocks
(all p > 0.05). There was significant plasticity of the P1
(F1,28= 8.36, p= 0.007), N1 (F1,28= 4.88, p= 0.036), and
P1–N1 (F1,28= 34.95, p < 0.001) amplitudes in controls
(Supplementary Figure 1A), but not in patients (Supple-
mentary Figure 1B; all p > 0.05). Relative to controls, there
was significantly reduced P1–N1 plasticity (F1,43= 13.82,
p= 0.001) and a trend towards reduced P1 plasticity that
did not reach significance (p= 0.065) in patients (Sup-
plementary Figure 1C), consistent with the previously
published results for the whole sample (n= 66)29. There
was a significant negative correlation of P1 and N1
amplitudes in controls (r=−0.64, p < 0.001) and in
patients (r=−0.77, p < 0.001).
VEP plasticity of the longitudinal sample at follow-up
At follow-up, checkerboard reversal stimulation pro-
duced the expected VEP amplitudes at the premodulation
blocks, with C1 at 88.1 ± 0.9 msec (mean ± s.e.m), P1 at
114.3 ± 0.8 msec, and N1 at 147.1 ± 1.9 msec in controls
(Fig. 2a) and with C1 at 87.4 ± 1.6 msec, P1 at 114.3 ±
1.3 msec, and N1 at 151.0 ± 3.1 msec in patients (Fig. 2b).
There were no differences between patients and controls
in the latencies of the premodulation or postmodulation
amplitude peaks (all p values > 0.05). P1 and N1 latencies
of the postmodulation blocks were significantly increased
relative to the premodulation latencies in controls (115.8
± 0.8 msec vs. 114.3 ± 0.8 msec, F1,28= 11.17; p= 0.002
and 150.5 ± 1.8 msec vs. 147.1 ± 1.9 msec, F1,28= 32.31;
p < 0.001, respectively). There were no significant latency
changes in patients and no significant effect of group
on changes in latencies from premodulation to
postmodulation blocks (all p values > 0.05). Patients had
significantly greater P1–N1 amplitude at the premodula-
tion blocks than controls (F1,43= 4.51; p= 0.04), whereas
no significant group differences were found for the C1, P1,
or the N1 premodulation amplitudes (all p > 0.05). There
was significant plasticity of the P1 (F1,28= 5.31, p= 0.03),
N1 (F1,28= 7.89, p= 0.009), and P1–N1 (F1,28= 157.48, p
< 0.001) amplitudes in controls, but not in patients (all p
> 0.05). In controls, the P1–N1 plasticity effect was sig-
nificant for all postmodulation blocks (postmodulation
block 1: F1,28= 124,25, p < 0.001, block 2: F1,28= 16.13, p
< 0.001, block 3: F1,28= 13.25, p= 0.001, block 4: F1,28=
5.10, p= 0.032, block 5: F1,28= 15.43, p= 0.001, and
block 6: F1,28= 15.42, p= 0.001; thus five out of six blocks
surviving Bonferroni correction, p < 0.05/6) (Figure S2A).
There was a significant negative correlation between
modulation of P1 and N1 amplitudes in controls (r=
−0.72, p < 0.001) and in patients (r=−0.50, p= 0.047).
There was significantly reduced P1–N1 plasticity (F1,43=
16.26; p < 0.001) and a trend towards reduced P1 plasticity
(F1,43= 3.48; p= 0.07), in patients relative to controls
(Fig. 2c). There was no significant group-salivary cortisol
level interaction, group-premodulation amplitude inter-
action or group-educational level interaction for P1–N1
plasticity (all p’s > 0.1), and the group difference remained
significant after adjusting for these covariates (F1,34=
8.51, p= 0.006).
Temporal stability of VEP plasticity in controls and patients
In controls, there was a significant association between
P1 plasticity at baseline and follow-up (r= 0.53, p= 0.003;
ICC3.1= 0.53; Fig. 2d). There was also a significant rela-
tionship between N1 plasticity at baseline and follow-up
(r= 0.57, p= 0.011; ICC3.1= 0.47; Fig. 2e), whereas no
significant association was found for P1–N1 plasticity (r
= 0.11, p= 0.57; ICC3.1= 0.11; Fig. 2f), in controls. In
patients, there were no significant associations for P1 or
N1 plasticity (r=−0.27, p= 0.30; ICC3.1=−0.27 and r=
−0.03, p= 0.093; ICC3.1= 0.03, respectively, Fig. 2g, h),
yet a significant association for P1–N1 plasticity was
found (r= 0.57, p= 0.022; ICC3.1= 0.55; Fig. 2i), when
the baseline and follow-up VEP plasticity results were
compared.
Explorative longitudinal analyses
There was no significant effect of time and no sig-
nificant group×time interaction effect on P1, N1, or
P1–N1 plasticity (all p > 0.05). There was no significant
effect of adding a psychotropic drug on VEP plasticity
changes from baseline to follow-up (patients unmedicated
at baseline and medicated at follow-up (n= 5) vs. other
patients (n= 11) vs. controls (n= 29); all p > 0.05; see also
Table S5 for details). There were no significant associa-
tions between P1, N1, or P1–N1 plasticity at baseline and
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number of depressive and hypomanic episodes between
baseline and follow-up (all p > 0.05).
VEP plasticity and saliva cortisol of the cross-sectional
sample at follow-up
Saliva cortisol
The saliva cortisol analyses showed the expected
morning awakening response in patients and controls at
follow-up (Fig. 3a); there was no significant group differ-
ence in the awakening response (p= 0.37). Saliva cortisol
averaged across the three collections was higher in
patients than controls (F1,53= 5.35, p= 0.025) and saliva
cortisol at 12:30 PM was significantly increased in patients
(F1,55= 6.59, p= 0.013).
VEP plasticity and clinical variables
In the cross-sectional sample at follow-up, controls (Fig.
2a) and patients (Fig. 4a) showed the expected C1 at 87.4
± .7 msec, P1 at 114.2 ± 0.6 msec, and N1 at 149.8 ±
1.5 msec after the checkerboard reversal. Patients had
significantly greater N1 (F1,56= 4.33, p= 0.04) and P1–N1
(F1,56= 13.74, p < 0.001) amplitudes at the premodulation
blocks than controls. There were no significant differ-
ences in premodulation N1 (13.6 μV and 9.9 μV in
unmedicated and medicated patients, respectively) or
P1–N1 (16.7 μV and 14.5 μV in unmedicated and medi-
cated patients) amplitudes between unmedicated and
medicated patients (see also Tables S1 and S2 for details).
Premodulation N1 amplitude was larger in unmedicated
patients than in controls and there were no significant
difference in N1 amplitude when medicated patients and
controls were compared (Table S1). Premodulation
P1–N1 amplitude was significantly increased in both
unmedicated and medicated patients relative to controls
(both p < 0.05; Table S2). No significant group differences
were found for the C1 or P1 premodulation amplitudes
(both p > 0.05). Patients had lower C1 amplitudes at the
postmodulation blocks than premodulation (F1,26= 11.73,
p= 0.002); no P1, N1, or P1–N1 plasticity was found in
the patient group (all p > 0.32); however, there was a
significant effect of modulation on P1–N1 amplitude in
the first postmodulation block (F1,28= 10.74, p= 0.003;
Figure S2B).There was a significant correlation between
modulation of P1 and N1 amplitudes in patients (r=
−0.53, p= 0.003). There was significantly reduced plas-
ticity of the N1 (F1,56= 4.26; p= 0.04) and the P1–N1
amplitudes (F1,56= 8.76; p= 0.005) in patients relative to
controls (Fig. 4b). For P1–N1 plasticity, the group dif-
ference was significant for the first (F1,56= 5.24, p=
0.026), second (F1,56= 5.42, p= 0.024) and last post-
modulation block (F1,56= 14.36, p < 0.001, surviving
Bonferroni correction for the six blocks tested). There was
no significant group-salivary cortisol level interaction or
group-premodulation amplitude interaction for P1–N1
plasticity (both p’s > 0.3), and the group difference
remained significant after adjusting for these covariates
(F1,51= 9.16, p= 0.004), whereas the N1 plasticity did not
(p= 0.10). There was no significant effect of medication
use (controls vs. unmedicated vs. medicated patients) on
N1 plasticity (F2,55= 2.84, p= 0.067), however, there was
a significant main effect of medication on P1–N1 plasti-
city (F2,55= 4.30, p= 0.018). Post hoc analyses demon-
strated significantly reduced plasticity in medicated
patients (n= 22) relative to controls (p= 0.027, Bonfer-
roni corrected). There was, however, no significant dif-
ference between unmedicated patients (n= 7) and control
subjects (p= 0.199, Bonferroni corrected) or between
medicated and unmedicated patients (p= 1.00, Bonfer-
roni corrected; see also Tables S3 and S4 for details).
Then, we found negative associations between P1 and
P1–N1 plasticity and MADRS score in patients, indicating
stronger impairments in plasticity in more severely
Fig. 3 Saliva cortisol and VEP plasticity. a Saliva cortisol was collected the day after the VEP experiment at three times: immediately after
awakening in the morning, 30 min after the first collection, and at 12:30 PM. Saliva cortisol was averaged across the three collections and was
significantly increased in patients with BD type II relative to controls. b In controls, there was a significant positive correlation between saliva cortisol
and plasticity of the P1–N1 amplitude, indicating greater plasticity with higher cortisol levels. c There was also a significant positive correlation
between the cortisol awakening response and plasticity of the P1–N1 amplitude in controls. VEP, visual evoked potential. BD, bipolar disorder
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depressed patients (r=−0.39, p= 0.04 and r=−0.40, p
= 0.03; Fig. 4c, d). There were no significant associations
between VEP plasticity and YMRS score in patients (all p
> 0.05; Figure S3). Next, we found decreased N1 (F1,46=
4.51, p= 0.04) and P1–N1 (F1,46= 4.83, p= 0.03) plasti-
city in the euthymic patients (n= 19) relative to controls
(Fig. 4e), which remained significantly reduced after
adjusting for saliva cortisol and premodulation amplitudes
(all p < 0.05). There were no significant differences in VEP
plasticity between patients with and without panic dis-
order or social phobia (all p > 0.05).
VEP plasticity and saliva cortisol
In controls, there was a positive association between
averaged saliva cortisol and P1–N1 plasticity (r= 0.43, p
= 0.023; Fig. 3b) and a positive association between the
cortisol awakening response and P1–N1 plasticity (r=
0.44, p= 0.018; Fig. 3c), indicating greater plasticity with
increasing cortisol levels. In patients, there was a trending
positive correlation between averaged saliva cortisol and
P1–N1 plasticity that did not reach statistical significance
(rho= 0.33, p= 0.096).
Discussion
Plasticity of the VEP is a promising assay for non-
invasive examination of cortical LTP-like synaptic pro-
cesses24,25. In the present study of VEP plasticity in
individuals with BD type II and controls, there were three
main findings. First, we reproduced impaired VEP plas-
ticity in BD type II at the follow-up examinations. We also
found that VEP plasticity was reduced in euthymic
patients and was negatively correlated with depression
severity. Second, we showed that saliva cortisol was
increased in BD type II, that VEP plasticity remained
impaired in patients after controlling for saliva cortisol,
and that saliva cortisol was positively correlated with
plasticity of the VEP in controls. Finally, plasticity of the
P1 and N1 components of the VEP, but not the P1–N1
component, exhibited moderate temporal stability in
healthy individuals when baseline and follow-up exam-
inations were compared.
Although its precise neural basis remains unknown, BD
has been conceptualized as a genetically influenced dis-
order of synaptic function and plasticity in limbic-cortical
neural networks involving the amygdala, hippocampus,
Fig. 4 VEP plasticity of the cross-sectional sample at follow-up. a Grand average premodulation (blue) and postmodulation (red) VEP in patients
with BD type II (n= 29). In contrast to controls, there was no significant P1, N1, or P1–N1 plasticity in the patient group. The VEPs for the controls are
shown in Fig. 2a (the longitudinal and cross-sectional sample at follow-up was identical. b N1 and P1–N1 plasticity were significantly reduced in
patients with BD type II relative to controls. P1–N1 plasticity remained reduced in patients after controlling for saliva cortisol and premodulation
amplitudes. *p= 0.04 **p= 0.005. Error bars represent the s.e.m. c There were significant negative correlations between P1 plasticity and MADRS
score and d P1–N1 plasticity and MADRS score in patients with BD type II, indicating stronger impairments in plasticity in more severely depressed
patients. e N1 and P1–N1 plasticity were significantly reduced in euthymic patients with BD type II (n= 19) relative to controls; these reductions
remained significant after controlling for saliva cortisol and premodulation amplitudes. *p < 0.05. Error bars represent the s.e.m. VEP, visual evoked
potential. BD, bipolar disorder. MADRS, Montgomery–Asberg Depression Rating Scale
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and prefrontal cortices9,14,45. In support of this hypothesis,
genetic studies have linked BD risk to genes implicated in
synaptic function and plasticity regulation46–51. Further
evidence for impaired synaptic function and plasticity in
BD was found in rodent models of depression (which may
reflect mechanisms relevant for the depressive phases of
BD)16,17, in studies of the cellular targets of anti-
depressants and mood stabilizers18,22,52,53, and in post
mortem studies of BD54,55.
Consistent with impaired synaptic function in BD, we
previously observed decreased VEP plasticy in BD type II
at the baseline examination29. Specifically, we found
plasticity of the P1, the N1, and the P1–N1 amplitudes in
controls and reduced P1–N1 plasticity in patients29. In
the present study, we reproduced impaired P1–N1 plas-
ticity in an overlapping sample of individuals with BD type
II at follow-up on average 2.2 years after the baseline
examinations29. We also found that VEP plasticity was
decreased in euthymic patients. Moreover, P1 and P1–N1
plasticity correlated negatively with MADRS score, indi-
cating lower plasticity in more severely depressed
patients. Together, these results suggest that VEP plasti-
city is impaired in the euthmic phases of BD type II and
may further deteriorate during depressive episodes. In
contrast, there were no significant associations between
hypomania severity and VEP plasticity. Yet, the hypoma-
nia symptoms of the patients were generally mild and
further studies are needed to clarify the relationship
between hypomania and VEP plasticity.
Another finding of the present study was increased
saliva cortisol in BD type II. This observation is consistent
with two recent meta-analysis, which found elevated sal-
iva and blood cortisol in BD, particularly in euthymic and
manic patients56,57. These studies involved individuals
with BD type I or mixed samples of patients with BD type
I or II56,57 and we are not aware of any previous cortisol
study that has been limited to BD type II.
The effects of glucocorticoids on synaptic function and
plasticity oftentimes follow an inverted U-shaped
curve37,38. At low and high levels, glucocorticoids can
impair synaptic function and plasticity, whereas normal
glucocorticoid concentrations facilitate synaptic plasticity
processes, such as LTP. These synaptic corticosteroid
effects are likely mediated by both non-genomic, e.g., by
pre- and postsynaptic modulation of glutamatergic
transmission, and genomic mechanisms37,38. The well-
established effects of glucocorticoids on synaptic function
raise the possibility that the elevated cortisol underlies
VEP plasticity impairments in BD type II. However, we
found no significant association between saliva cortisol
and VEP plasticity in the individuals with BD type II and
their plasticity reduction remained significant after con-
trolling group analyses for cortisol. Together, these find-
ings indicate that impaired plasticity of the VEP in BD
type II is not caused by elevated cortisol and other
potential mechanisms should be addressed in future stu-
dies. In particular, BD risk genes have been linked to
synaptic function and plasticity regulation46–51 and
investigations of whether and how BD risk variants affect
plasticity of the VEP are warranted.
We also found significant correlations between VEP
plasticity and averaged saliva cortisol and the cortisol
awakening response in controls (Fig. 3). Although spec-
ulative, these positive associations could reflect the
ascending part of an inverted U-shaped relationship
between cortisol and synaptic plasticity. This hypothesis
could be tested in future studies of VEP plasticity by
including more individuals with higher stress and cortisol
levels than the present work. To our knowledge, there is
no other study of cortisol and plasticity of the VEP, yet
two previous studies reported significant relationships
between cortisol and TMS-induced motor cortex plasti-
city44,58. Sale et al.58 found that motor cortex plasticity
was greater in the evening (when endogenous cortisol is
lower) than in the morning and that an oral dose of
hydrocortisone blocked the motor cortex plasticity. Clow
et al.44 observed a positive association between the cor-
tisol awakening response and TMS-induced motor cortex
plasticity, consistent with the results of the present study.
Based on the current understanding of mood regulation
in humans59,60, it is unlikely that impaired visual cortex
synaptic plasticity is a central pathophysiological
mechanism in BD type II. Two important, yet unresolved
questions are therefore (1) to what extent does VEP
plasticity reflect plasticity in brain regions believed to be
important in mood disorders, such as prefrontal and
temporal cortices and (2) are the putative cortical synaptic
impairments in bipolar disorders confined to specific
mood regulation-related regions or widespread? To our
knowledge, no study has examined the association
between synaptic plasticity in prefrontal and temporal
regions and VEP plasticity. However, one recent investi-
gation found significant association between motor cortex
plasticity and VEP plasticity61. Moreover, previous post
mortem studies found evidence for synaptic impairments
in bipolar disorders in several cortical regions, including
prefrontal, temporal, and visual cortices55,62–66. In addi-
tion, the significant association between depression
severity and visual plasticity found in the present study
supports the notion that VEP plasticity might be used as
an indirect measure of synaptic impairments in mood
regulation-related cortical regions. Nevertheless, more
research is needed to clarify the relationship between VEP
plasticity and synaptic plasticity in cortices implicated in
mood regulation.
An unexpected finding of the present study was that
patients had greater N1 and P1–N1 premodulation
amplitudes than controls at follow-up. We examined
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whether use of psychotropic drugs could underlie the
premodulation amplitude increases and found, if any-
thing, a trend toward smaller premodulation amplitudes
in medicated than in unmedicated patients (see also
Tables S1 and S2 for details). In contrast, there were no
group differences in the premodulation amplitudes at
baseline29. The premodulation amplitude increase in
patients at follow-up should therefore be considered
cautiously and need to be confirmed by future research.
Another important question is whether the larger pre-
modulation amplitudes in patients at follow-up could be
related to their VEP plasticity reduction, e.g., owing to a
ceiling effect. However, the P1–N1 plasticity remained
significantly reduced in patients after adjusting for pre-
modulation amplitude. In addition, P1–N1 plasticity was
also significantly reduced in patients at baseline when
there were no group differences in the premodulation
amplitudes. Altogether, it seems unlikely that the
increased premodulation amplitude in patients underlie
their impaired P1–N1 plasticity observed at follow-up.
The field of noninvasive LTP-like cortical plasticity
assessment in humans is young and mainly encompasses
repetitive visual or auditory stimulation-induced plasticity
in sensory cortices (e.g., VEP plasticity), motor cortex
plasticity induced by TMS or transcranial direct current
stimulation (tDCS), and sleep slow wave activity (SWA) of
the EEG30,36,67–76. Previous studies found that TMS-
induced motor cortex plasticity was decreased in MDD77
and that tDCS might increase motor cortex plasticity in
depressed individuals78. Sleep SWA is another potential
EEG-based index of cortical synaptic plasticity72–76 and
increased SWA during sleep has been linked to the rapid
antidepressant response to ketamine treatment in MDD79.
Moreover, recent studies indicate that TMS and tDCS can
alter SWA80,81 and that acoustic stimulation might
enhance SWA during sleep74. Each of these methodolo-
gies has strengths and limitations and we chose VEP
plasticity in our studies because of its feasibility (e.g., no
requirement of sleep or magnetic stimulation) and since
detailed studies found that VEP plasticity in rodents
exhibits core features of LTP31–33.
The temporal stability of these noninvasive plasticity
indices remains to be clarified and there has, to our
knowledge, been no previous longitudinal study of sen-
sory cortex LTP-like plasticity. There is also a scarcity of
studies examining the test–retest reliability of other
noninvasive plasticity indices and the limited TMS-
induced motor cortex plasticity literature observed sub-
stantial variability82. For example, Fratello et al.83 found
low temporal stability when TMS-induced motor cortex
plasticity was measured twice in healthy volunteers with a
1 week test–retest interval (ICC= 0.05). Thus, the results
of the present study indicating moderate temporal stabi-
lity of both the P1 and the N1 plasticity (ICC between 0.5
and 0.6) in controls with a test–retest interval of 2.2 years
period are promising. These ICC’s are also comparable to
the reliability commonly found in functional magnetic
resonance imaging studies with test–retest intervals of
weeks to months (ICC usually between 0.33 and 0.66)84.
We note, however, that the temporal stability of P1–N1
was low in the controls of the current study. This finding
could be due to P1 and N1 modulation representing two
independent plasticity indices. However, we found that P1
and N1 plasticity were significantly negatively correlated,
which suggests that they may reflect at least partly over-
lapping mechanisms. We therefore speculate that the
poor reliability might be related to the fact that P1–N1
includes the variability of both the P1 and the N1 com-
ponent; this composite measure might thus have lower
temporal stability than the individual VEP components.
Thus, although the present results are promising, more
work is needed to clarify the test–retest reliability of VEP
plasticity in humans.
The present study comes with several limitations. First,
the sample size was modest and larger studies are needed
to clarify the relationships between VEP plasticity and
comorbid psychiatric illnesses and illness course. Second,
there were no significant differences in VEP plasticity
between medicated and unmedicated patients, yet the
number of unmedicated patients was small (n= 7), at
follow-up. Further studies are therefore needed to fully
clarify the effects of psychotropic drugs on VEP ampli-
tudes and plasticity. Third, the present study did not
include a BD type I or an MDD comparison group. More
research is therefore required to assess whether the VEP
plasticity impairments observed in patients of the present
study are specific for BD type II or common neurobio-
logical characteristics of mood disorders. Fourth, the
precise neural mechanisms underlying VEP plasticity in
humans remain to be fully clarified. However, rodent and
human studies strongly suggest that plasticity of the VEP
reflect cortical processes closely related to LTP24,25,31–33.
Fifth, our plasticity paradigm did not include a control
stimulus to test whether VEP modulation was dependent
on stimulation properties. However, frequency- and
pattern-specific VEP potentiation has been demonstrated
previously for the current paradigm28. Sixth, we employed
a limited number of electrodes. The use of high-density
EEG or magnetoencephalography may increase our
understanding of how modulation of cortical excitability
might change neural circuitry in mood disorders. Seventh,
whereas VEP plasticity was examined longitudinally, sal-
iva cortisol was measured only at follow-up. Finally, future
research could also examine whether other stress-related
indices are associated with VEP plasticity, such as hair
cortisol, heart rate variability, and alpha-amylase levels.
In conclusion, the present study provides additional
evidence for impaired LTP-like cortical plasticity in BD
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type II, suggests that impaired cortical plasticity is present
in the euthymic phases of the illness and may further
deteriorate during depressive episodes, and indicates that
elevated cortisol does not underlie the plasticity impair-
ment. The results also suggest a positive association
between the VEP plasticity and saliva cortisol in controls,
possibly reflecting an inverted U-shaped relationship
between cortisol and synaptic plasticity. From a metho-
dological perspective, converging lines of evidence indi-
cate that synaptic dysfunction is a central
pathophysiological mechanism across psychiatric ill-
nesses9–13 and there is therefore a substantial need for
techniques, which enable assessment of cortical synaptic
function and plasticity in humans. The previous24,25,28–30
and present works together suggest that VEP plasticity is
an accessible method for noninvasive studies of LTP-like
cortical processes, which may help elucidate the patho-
physiological and clinical significance of synaptic dys-
function in psychiatric disorders.
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